前列腺移行区纤维化与MTOPS研究中临床进展相关
研究分析MTOPS试验中接受安慰剂、多沙唑嗪、非那雄胺或联合治疗男性的移行区活检组织,用天狼星红双折射和CT-FIRE评估胶原含量与结构改变,发现高水平的波浪状排列胶原与多沙唑嗪联合非那雄胺组临床进展风险增加显著相关,尤其在高体重指数者中。
要点
- 高水平的波浪状排列前列腺移行区胶原与多沙唑嗪联合非那雄胺治疗者临床进展风险增加显著相关。
- 该关联在高体重指数参与者中尤为明显。
- 抗纤维化治疗可能为对当前药物治疗无反应的下尿路功能障碍男性提供新方法。
核心结论
- 前列腺移行区纤维化改变与接受多沙唑嗪联合非那雄胺治疗的男性临床进展风险增加相关。
- 作者认为抗纤维化治疗可能为对当前药物治疗无反应的下尿路功能障碍男性提供新的治疗途径。
研究设计与样本
- 研究使用MTOPS试验中接受安慰剂、多沙唑嗪、非那雄胺或联合治疗且有无临床进展男性的移行区活检组织。
- 采用天狼星红双折射和CT-FIRE分析评估胶原含量与结构改变,并与标注的人口学和临床数据进行相关性分析。
- 统计分析使用皮尔逊相关系数、方差分析和t检验。
主要发现
- 高水平的波浪状、排列的前列腺移行区胶原与多沙唑嗪联合非那雄胺组MTOPS试验参与者临床进展风险增加显著相关,尤其在高体重指数者中。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Medications targeting androgen receptor activity (eg finasteride) or smooth muscle contractility (eg doxazosin) do not resolve lower urinary tract symptoms indicative of lower urinary tract dysfunction in an important subgroup of men. Recently fibrosis has been implicated as another pathobiology contributing to male lower urinary tract symptoms but to our knowledge no systematic studies have been done to assess fibrosis in the context of medical treatment. We determine whether fibrotic changes in the prostate transition zone are associated with an increased risk of clinical progression in participants treated with doxazosin, finasteride or finasteride plus doxazosin in the MTOPS (Medical Therapy of Prostatic Symptoms) study. MATERIALS AND METHODS: Transition zone biopsy tissues from men who did or did not experience clinical progression on placebo, doxazosin, finasteride or combination therapy were assessed for collagen content and architectural changes using picrosirius red birefringence and CT-FIRE (Curvelet Transform-Fiber Extraction) analysis. Correlations were made with annotated demographic and clinical data. Statistical analyses were done with the Pearson correlation coefficient, ANOVA and the t-test. RESULTS: High levels of wavy, aligned prostate transition zone collagen significantly correlated with an increased risk of clinical progression among MTOPS trial participants treated with doxazosin plus finasteride, particularly those with a high body mass index. CONCLUSIONS: Fibrotic changes in the prostate transition zone are associated with an increased risk of clinical progression in men treated with doxazosin plus finasteride. Antifibrotic therapeutics might provide a new treatment approach in men with lower urinary tract dysfunction who do not respond to current medical treatment approaches.
引用
- Macoska JA, Uchtmann KS, Leverson GE, et al. Prostate Transition Zone Fibrosis is Associated with Clinical Progression in the MTOPS Study. J Urol. 2019. PMID: 31188728. doi:10.1097/JU.0000000000000385
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。